Helen Webster

Helen Webster

Auto-generated profile, based on publicly available information

Helen Webster

Duke Human Vaccine Institute, Duke University Medical Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 September 2021 in Vaccine
Verified
Journal Article
Closed access
HWHelen Webster
Helen Webster
SVSarah Valencia
Sarah Valencia
AKAmit Kumar
Amit Kumar
CCCliburn Chan
Cliburn Chan
MDMaria Dennis
Maria Dennis
SPSallie Permar
Sallie Permar

6 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
XHXintao Hu
Xintao Hu
KKKrithika P. Karthigeyan
Krithika P. Karthigeyan
SHSavannah Herbek
Savannah Herbek
SVSarah M. Valencia
Sarah M. Valencia
JJJennifer A. Jenks
Jennifer A. Jenks
SPSallie Permar
Sallie Permar
Background: The MF59-adjuvanted gB subunit (gB/MF59) vaccine demonstrated ~50% efficacy against human cytomegalovirus (HCMV) acquisition in multiple clinical trials, suggesting efforts to improve this vaccine design might yield a vaccine suitable for licensure. A vaccine candidate employing nucleoside-modified mRNAs encoding HCMV gB and pentameric complex (PC) encapsulated in lipid nanoparticle, mRNA-1647, is currently in late-stage efficacy trials. Yet, its immunogenicity has not been compared to the partially-effective gB/MF59 vaccine. Methods: We assessed neutralizing and Fc-mediated IgG effector antibody responses induced by mRNA-1647, a vaccine comprising an equal mass of 6 mRNAs encoding gB and PC antigens, in both HCMV seropositive and seronegative vaccinees from a first-in-human clinical trial through 1-year following 3 rd vaccination using a systems serology approach. Further, we compared peak anti-gB antibody responses in seronegative mRNA-1647 vaccinees to that of seronegative female adolescent gB/MF59 vaccine recipients. Results: mRNA-1647 vaccination boosted pre-existing HCMV-specific IgG responses in seropositive vaccinees, including neutralizing and Fc-mediated effector antibody responses. In seronegative vaccinees, mRNA-1647 induced durable and functional HCMV-specific IgG responses. Elicited gB-specific IgG responses were lower than the PC-specific IgG responses. Additionally, gB-specific IgG and antibody-dependent cellular phagocytosis (ADCP) responses were lower than those elicited by gB/MF59. However, mRNA-1647 elicited robust neutralization and high antibody-dependent cellular cytotoxicity (ADCC) responses. Conclusions: mRNA-1647 vaccination induced polyfunctional and durable HCMV-specific antibody responses. mRNA-1647-elicited gB-specific IgG responses were lower than PC-specific IgG responses and lower than those elicited by the partially effective gB/MF59. However, higher neutralization and ADCC responses were elicited by mRNA-1647 than gB/MF59. Clinical Trials Registration: ClinicalTrials.gov ( NCT03382405 , mRNA-1647) and ( NCT00133497 , gB/MF59). Summary: mRNA-1647 HCMV vaccine elicited polyfunctional and durable antibody responses in humans. While the mRNA-1647-elicited glycoprotein B (gB)-specific IgG responses were lower than that of the moderately-effective gB/MF59 vaccine, the pentameric complex (PC)-specific IgG responses were strong.